Literature DB >> 18239761

Abnormal PSA tests--delays in referral.

Alan M F Stapleton1, Richard L Johns, Tina Kopsaftis, David J Tamblyn, Carole B Pinnock.   

Abstract

BACKGROUND: The main benefit of prostate specific antigen (PSA) testing is to help detect prostate cancer at an early, curable stage. Delays between the first abnormal PSA test and biopsy can undermine that benefit, but have not yet been studied. We investigated delays before biopsy together with associated PSA increases as an indicator of disease progression.
METHODS: We identified 241 patients with a primary care referral because of an elevated PSA result (>4 ng/mL) and no previous prostate biopsy. Prostate specific antigen results and intervals between PSA testing, specialist clinic referral, appointment and biopsy were stratified by age.
RESULTS: Median times between first abnormal PSA, referral, consultation and biopsy were modest but associated with increases in PSA. Extended delays (>20 months) between first abnormal PSA and referral occurred in 25% of younger men. A PSA result less than 10 ng/mL was the best predictor of a delay to refer. DISCUSSION: Rising PSA and possible cancer progression during investigation for prostate cancer suggest that prompt care is advisable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239761

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  1 in total

1.  Prostate cancer outcomes and delays in care.

Authors:  Michael E O'Callaghan; Zumin Shi; Tina Kopsaftis; Kim Moretti
Journal:  Int Urol Nephrol       Date:  2017-01-12       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.